BusinesseFFECTOR Publishes the Design and Profile of eFT508 in Peer Reviewed Journal of Medicinal ChemistryBy Nasdaq OMXApr 26, 2018, 11:31 AM UTC
BusinesseFFECTOR Presents Data on the Discovery and Structure of eFT226, a Novel Inhibitor of eIF4A, at the AACR 2018 Annual MeetingBy Nasdaq OMXApr 16, 2018, 12:01 PM UTC
BusinesseFFECTOR Announces Appointment of John W. Smither to its Board of DirectorsBy Nasdaq OMXMar 23, 2018, 6:00 PM UTC
BusinessClinical Data for eFFECTOR Therapeutics’ Lead Candidate eFT508 Demonstrates Clinical Activity, Well-Tolerated Safety ProfileBy Nasdaq OMXDec 11, 2017, 3:00 PM UTC
BusinesseFFECTOR Therapeutics Presents Preclinical Data for eFT508 that Demonstrates Beneficial Immunological EffectsBy Nasdaq OMXNov 10, 2017, 3:00 PM UTC
BusinesseFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal CancerBy Nasdaq OMXOct 4, 2017, 2:00 PM UTC
BusinessCellular Biomedicine Group (CBMG) Announces the Addition of a Second Clinical Site in the Expansion of its Chimeric Antigen Receptor T-cell (CAR-T) Phase I Clinical Trial for Its CARD-1 Trial in Patients with Non-Hodgkin Lymphoma (NHL)By Nasdaq OMXMay 15, 2017, 10:22 AM UTC
BusinessCellular Biomedicine Group (CBMG) Approved to Commence Phase I Trial (CARD-1) for C-CAR011 in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL) in ChinaBy Nasdaq OMXNov 29, 2016, 12:16 PM UTC
